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As a Source of Oxidative Stress
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Abstract
Significance: Stroke, a leading cause of death and disability, poses a substantial burden for patients, relatives,
and our healthcare systems. Only one drug is approved for treating stroke, and more than 30 contraindications
exclude its use in 90% of all patients. Thus, new treatments are urgently needed. In this review, we discuss
oxidative stress as a pathomechanism of poststroke neurodegeneration and the inhibition of its source, type 4
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX4), as a conceptual breakthrough in
stroke therapy. Recent Advances: Among potential sources of reactive oxygen species (ROS), the NOXes stand
out as the only enzyme family that is solely dedicated to forming ROS. In rodents, three cerebrovascular NOXes
exist: the superoxide-forming NOX1 and 2 and the hydrogen peroxide-forming NOX4. Studies using NOX1
knockout mice gave conflicting results, which overall do not point to a role for this isoform. Several reports find
NOX2 to be relevant in stroke, albeit to variable and moderate degrees. In our hands, NOX4 is, by far, the major
source of oxidative stress and neurodegeneration on ischemic stroke. Critical Issues: We critically discuss the
tools that have been used to validate the roles of NOX in stroke. We also highlight the relevance of different
animal models and the need for advanced quality control in preclinical stroke research. Future Directions: The
development of isoform-specific NOX inhibitors presents a precious tool for further clarifying the role and
drugability of NOX homologues. This could pave the avenue for the first clinically effective neuroprotectant
applied poststroke, and even beyond this, stroke could provide a proof of principle for antioxidative stress
therapy. Antioxid. Redox Signal. 18, 1418–1427.
Relevance of Stroke and Lack of Treatment Options
Stroke is one of the most common pathologies in the in-dustrialized world and ranks as the second frequent cause
of death after heart disease. Due to an aging population, ab-
solute numbers are further increasing, even though preva-
lence is slightly decreasing. Apart from the individual
suffering and burden to partners and families, each stroke
patient costs the U.S. healthcare system about U.S. $140,048
for initial care, rehabilitation, and follow-up care of lasting
disabilities (51).
There are various risk factors for stroke, including non-
modifiable ones such as age, race, or genetic background, and
modifiable ones such as hypertension, poor diet, smoking,
lack of exercise, obesity, hypercholesterolemia, and diabetes
(22). In the clinic, stroke is presented in two major forms:
either ischemic (*85% of the cases), in which a vessel be-
comes occluded by a blood clot or by vascular dissection, or
hemorrhagic caused by intracerebral (*10%) or subarach-
noidal (*3%) bleedings. In this review, we will focus on the
more common ischemic stroke.
Already 5 min after the onset of ischemia, neurons begin
to die. Therefore, blood flow should be restored as early
as possible. For this, recombinant tissue plasminogen acti-
vator (rt-PA) is applied intravenously, in order to lyse the
occluding blood clot. Indeed, it is the only drug that is cur-
rently approved for acute stroke treatment and, signifi-
cantly, neuroprotective therapies are not available at all.
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Moreover, only a limited number of patients benefit from rt-
PA, as rt-PA may be administered to patients unless several
requirements are met. First, a computed tomography (CT)
scan should be performed to exclude a hemorrhagic stroke,
in which case rt-PA would exacerbate bleeding. Second,
rt-PA should be administered within the first 3–4.5 h after
the cerebrovascular incident. This, however, represents a
challenge given the very narrow time window to recognize
the stroke, transportation to the hospital, and completing the
CT examination. Third, several additional contra-indications
exist, for example, an age older than 80 years, increased risk
of bleeding, previous surgeries, and so on. Thus, the use of
rt-PA is finally restricted to only approximately 10% of all
stroke patients. For this reason, other improved thromobo-
lytic drugs are currently under investigation. They are
characterized by longer half life and higher fibrin specificity
and, hence, a possibly lower risk of bleeding. However, re-
cent clinical trials were disappointing (38). Therefore, in or-
der to find effective treatment options in stroke, we need to
identify novel mechanism-based targets. One such promis-
ing candidate mechanism is oxidative stress.
The Oxidative Stress Hypothesis
Oxidative stress refers to a relative surplus of reactive ox-
ygen species (ROS) caused by excessive ROS generation and/
or impaired ROS degradation. Under conditions of oxidative
stress, the overload of ROS becomes detrimental and possibly
contributes to various acute and chronic diseases, such as
myocardial infarction, hypertension, atherosclerosis, cancer,
neurodegeneration, and inflammation. Consequently, oxida-
tive stress has also been suggested as a key underlying
mechanism of ischemic stroke (11).
The brain is particularly sensitive to oxidative stress be-
cause of its high oxygen consumption and low oxidative de-
fence capacity (20). In stroke, ischemia-derived nutrient and
oxygen deficiency lead to cellular energy failure and neuronal
damage. Reperfusion even aggravates this damage, because
the freshly arriving oxygen will serve as a substrate for new
ROS production (10).
Based on the hypothesis that oxidative stress plays a major
role in neuronal damage caused by ischemic stroke, clinical
trials using antioxidant treatments in an attempt to scavenge
ROS were performed. However, despite promising preclinical
results and even a first rather promising, although under-
powered, Phase III trial (37), these studies eventually failed to
show a significant amelioration in stroke patients (56). Pos-
sible explanations for the negative outcome of antioxidants in
clinical trials are detailed elsewhere (71).
However, one important consideration is that ROS are not
always associated with deleterious effects and under physi-
ological conditions, they appear to also have essential func-
tions, for example, within the innate immune response (24),
cellular signaling, control of cellular proliferation and differ-
entiation, oxygen sensing, vascular tone, and angiogenesis.
Consequently, interfering with these beneficial roles of ROS in
a too broad and unspecific manner can result in pathologies as
well, a phenomenon termed as reductive stress.
Since these nonspecific antioxidative therapies were un-
successful in the clinic, the oxidative stress hypothesis still
remains unproven. Nevertheless, the failure of antioxidant
trials, even in stroke patients (15), does not disprove the in-
volvement of ROS in ischemia-reperfusion (I/R) injury. Ra-
ther, it may demonstrate that a much deeper understanding of
the underlying mechanisms and more focused, molecular
approaches on relevant molecular sources of oxidative stress
are needed.
NADPH Oxidases As a Relevant Source
of Oxidative Stress in Stroke
A superior approach for using antioxidants and scavenge
ROS in a generalized, nonselective manner would be to spe-
cifically inhibit the disease-relevant enzymatic source(s) of
ROS formation and leave physiological ROS signaling intact.
In the central nervous system, ROS can derive from different
sources, including mitochondria, xanthine oxidase, un-
coupled nitric oxide synthase (NOS), and cyclooxygenase
(68). However, NADPH oxidases are the only known enzyme
family with the single known function of producing ROS.
All other enzymes produce ROS as a by-product or on
uncoupling.
NADPH oxidases are multicomponent protein complexes
containing a catalytic NOX subunit that transfers electrons
from NADPH to oxygen, thereby forming ROS (6). Five NOX
isoforms exist, NOX1-5. Two additional proteins, DUOX1 and
DUOX2, also contain an oxidase domain, which in this case is
linked to a peroxidase-like domain. Their roles in vascular
biology are unclear. NOX homologues differ not only in their
tissue and (sub)cellular localization, which is an important
determinant of their function, but also in their requirements
for regulatory subunits and the nature of the ROS produced
(46). Since many reviews on NADPH oxidases have been
published, we will not discuss in great detail the characteris-
tics of the different NOX homologues but rather refer to recent
reviews (49, 59).
Of the five NOX isoforms, NOX3 is most likely not relevant
in I/R injury, as it is mainly expressed in the inner ear but not
in blood vessels. In contrast, NOX1, NOX2 (previously termed
gp91phox), and NOX4 are expressed under physiological
conditions in the central nervous system, including intracra-
nial vessels and neuronal tissues (1, 28). Based on mRNA
levels, NOX4 is the most widely distributed NOX isoform in
the vasculature. Its expression is an order of magnitude higher
in cerebral arteries compared with peripheral blood vessels
(42). With regard to the NOX5 isoform, it should be noted that
NOX5 is not expressed in rats and mice and is, therefore,
functionally less characterized than others. Nevertheless,
NOX5 is of considerable interest, as it is both expressed in the
human vasculature and regulated in a unique manner, that is,
direct binding of calcium, which may be of pathomechanistic
relevance, as an imbalance in calcium homeostasis appears to
be decisive for neuronal cell death after an ischemic stroke.
The absence of NOX5 in the rat and mouse genome is,
therefore, a noteworthy limitation of all preclinical studies in
these species.
Since specific antibodies for the various isoforms are scarce,
most papers are limited to measuring NOX mRNA levels.
Since NOX activities are also highly regulated at a post-
translational level, protein expression and activity data are
much more favorable. For example, increased NOX activity
does not necessarily require increased subunit expression,
although correlation of mRNA levels of NOX2 or NOX4 and
NADPH oxidase activity has been observed in transgenic




















































mice (4). After an ischemic stroke, NOX2 and NOX4 are up-
regulated within 24 h. It appears that in this process, NOX2
protein levels increase within microglia (23), and NOX4 pro-
tein levels increase in neurons and endothelial cells (33, 65)
(Fig. 1). This up-regulation might give a first indication of the
implication of NOX2 and 4 in stroke pathology, and, hence,
these two NOX isoforms present a potential target in stroke
therapy. Therefore, several research groups started investi-
gating the role of NADPH oxidases in stroke.
Lack of Quality Control in Preclinical Stroke Research
In 1996, rt-PA treatment has been approved for clot lysis in
stroke. Since then, no innovative stroke treatment has made it
to the clinic. O’Collins et al. provided an overview of the nu-
merous attempts of stroke researchers to develop neuropro-
tective drugs. They come to the alarming conclusion that 1026
experimental treatments have been investigated, from which
114 have even been clinically tested in stroke patients, but that
none of them has fulfilled their initial expectations (44). The
main reason is a quality issue with most, if not all, preclinical
stroke studies.
In preclinical models, stroke is induced artificially in
young, healthy animals; whereas in humans, stroke happens
in older patients, often as a consequence of several underlying
pathologies (e.g., hypertension, atherosclerosis, atrial fibrilla-
tion, etc.) (19), and spontaneous recanalization can occur.
Thus, neither permanent nor transient animal models of is-
chemic stroke fully mimic the clinical situation.
The majority of studies are performed in rodents due to
economical and ethical reasons, whereas pigs and primates
would be better suited because of their brains’ higher pro-
portion of white matter and gyrencephalic structure, which is
more similar to humans (26). Moreover, commonly used
preclinical ischemic stroke models are diverse. The method of
vessel occlusion, for example, differs from mechanical or
thermal to embolic or chemical (Fig. 2). Most preclinical
studies use the mechanical model of transient middle cerebral
artery occlusion. In addition, in many studies, the observation
period stops after about 24 h poststroke. This per definition
will not address long-term morbidity, mortality, and relevant
neurological outcomes.
Significantly, these limitations are not specific to stroke
research and hold true for almost all cardiovascular indica-
tions, where progress is poor in general. All major drug
groups have run out of patent, documenting an obvious
20 year-long innovation block. Thus, the successful transla-
tion of preclinical research, in general, requires conceptual
changes and quality improvement similar to clinical research
in the 70s.
Quality Management in Preclinical Stroke Studies
A group of basic and clinical researchers along with
representatives from the pharmaceutical industry formed
the Stroke Therapy Academic Industry Roundtable (STAIR)
to design preclinical study criteria that should be followed
to improve the quality of stroke studies and their later
translation into practice (60). Since human populations are
more heterogeneous compared with laboratory animals and
most stroke patients have diverse comorbidities, experi-
mental animals should ideally also present comorbidities in
order to better mimic clinical conditions. Furthermore, old
animals should be included, because stroke patients are also
mostly elderly people. At present, however, preclinical
studies mainly use young animals, presumably to reduce
time and costs. Significantly, not only age but also gender
plays a role in stroke pathology and/or drug metabolism.
Thus, both male and female animals should be assessed in
stroke studies. Further aspects that may have hampered
translation from animal to clinical studies are the endpoints
that are assessed in animals. While the infarct size is often
the major investigated parameter in animals, neurological
outcome is the most important endpoint in humans. Ac-
cordingly, functional studies should be performed up to
several weeks postcerebral I/R and survival monitored to
meet the criteria of clinical trials, rather than stopping
the observation period 24 h after ischemia. In addition, at
least one permanent and one transient model should be
performed to validate a stroke mechanism. Other quality
parameters include the verification of reduced blood flow
on vessel occlusion ( < 0.12 ml/g/min) and/or reperfusion,
as well as monitoring rectal temperature, because hypo-
thermia likely has neuroprotective effects in experimental
models (26), although there is actually no evidence from
clinical trials (14). The most important quality criteria for
preclinical stroke studies are summarized in Figure 3. Of
course, these strict requirements only apply for true trans-
lational and not for early proof of principle or purely
mechanistic studies.
FIG. 1. Cerebral expression pat-
tern of NOX isoforms implicated
in stroke. NOX2 is highly expressed
in inflammatory cells such as resi-
dent microglia and peripheral neu-
trophils, whereas NOX4 is rather
expressed in neurons. Both endo-
thelial cells and astrocytes seem to
express NOX homologues. Cerebral
NOX activation and subsequent re-
active oxygen species (ROS) gener-
ation contribute to blood-brain
barrier (BBB) disruption, inflamma-
tion, and postischemic neuronal in-
jury [adapted from Ref. (49)].




















































Similar to all preclinical experiments, randomization (only
performed in 36% of all stroke studies), allocation conceal-
ment (11%), and blinded analysis of the results (29%) should
be performed (54). Mortalities per experimental group need to
be explicitly stated, as this is both a quality criterion for the
animal surgery and may distort data representation when
only the phenotype of the surviving animals is reported.
Moreover, it has recently been recommended to conduct
preclinical studies both internationally and multicenter (16,
17). Finally, another aspect that should not be neglected is
publication bias (55). Negative findings are often not pub-
lishable or more difficult to publish, and the literature is, thus,
in favor of positive results, which may overestimate efficacy
of any experimental therapy.
Knockout Models to Validate the Role
of NOX in Stroke
Knockout (KO) models are powerful tools for determining
the role of different NOX isoforms, allowing assessment of a
causality-effect relationship. A general artifact is that in KO
mice the gene is deleted from the onset of stroke whereas any
therapy is likely to initiate only hours after the ischemic event.
Apart from this, even truncated proteins or splice variants
with residual activity may be generated, depending on the KO
strategy. When taking the example of our own NOX4 KO
model, we deleted the exons that code for the protein region
which is essential for NADPH binding (Fig. 4). Thus, NADPH
oxidase activity will be zero, irrespective of any truncated
protein being present (33). In addition, abolishing the ex-
pression of one NOX isoform may result in counter-regulation
of other NOX isoforms and ROS formation. Moreover, most
NOX proteins have several binding partners such as the
highly abundant p22phox. It is unclear whether p22phox’s sole
function relates to NOX. If not, the lack of one binding partner
of p22phox may have bystander effects on other p22phox-
binding proteins. Moreover genes flanking the target gene or
genetic background (due to random recombination) may also
lead to misinterpretations (18). Most genetically modified
mice have been generated on a 129 substrain, which was the
first to be easily genetically manipulated but has poor
breeding efficacy. Therefore, embryonic stem cells from a 129
strain are implanted into blastocysts of the well-breeding
C57BL6 strain. The resultant chimeric mouse will always have
some remaining genetic information from the 129 strain, even
after extensive backcrossing onto C57BL6 mice and extensive
SNP analysis. Thus, it cannot be excluded that some NOX KO
mice display a phenotype that is mistakenly attributed to the
deleted NOX gene. In this context, also the sub-strain on
which the mice have been backcrossed, that is, C57BL6J versus
C57BL6N showing different mitochondrial abnormali-
ties, may represent an important factor. Finally, not all
FIG. 2. Schematic overview of
preclinical stroke models. Rodent
stroke models have been estab-
lished with the aim of generating as
reproducible infarct sizes as possi-
ble. Each stroke model tries to
capture elements of human stroke,
though with many well-recognized
limits. The choice of the experi-
mental stroke model is optional, but
it is recommended to use at least
one permanent and one transient
ischemic stroke model. The use of
mice presenting comorbidities is
another recommended option.
FIG. 3. Recommended quality criteria for preclinical
stroke research. To date, animal stroke studies vary in
quality and reliability. Thus, when performing preclinical
stroke experiments, the quality criteria listed above should
be followed. Adherence to these criteria can be used to assess
the quality of experimental studies.




















































publications clearly state whether littermate mice have been
used as wild-type controls.
No implication of NOX1
With regard to a possible role of NOX1 in stroke, three
studies have been published that all used the same NOX1 KO
mouse strain (30, 31, 33), although not all studies reported
details according to the STAIR criteria. Jackman et al. con-
cluded that NOX1 is relevant for angiotensin-stimulated ROS
production but has no impact on overall ROS production,
stroke size, and neurological outcome (30). However, after a
subgroup analysis, the authors postulated that cortical strokes
were four times increased in NOX1 KO versus control mice,
possibly indicating that NOX1 may play a protective role by
limiting cortical damage. Another group reported opposite
findings, that is, reduced infarct size in NOX1 KO mice (31).
This effect was only visible when the ischemic period lasted
1 h but not when lasting longer. Interestingly, antioxidant
treatment showed additional neuroprotective effects in NOX1
KO mice and reduced infarct size to the same extent as in
apocynin-treated wild-type mice. Thus, the effect of scav-
enging ROS by antioxidants was unlikely mediated by NOX1
but rather by other NOX isoforms or non-NOX sources of
ROS. We observed neither a difference in infarct volume nor
in neurological behavior when investigating NOX1 KO mice
in stroke (33). Collectively, NOX1 appears to have no or only a
very minor effect on neurological damage after stroke. This is
consistent with the fact that NOX1, at least at the mRNA level,
is not up-regulated after cerebral I/R.
NOX4, the key player
Using our NOX4 KO mice, we unambiguously showed that
NOX4 is a pathologically relevant NOX isoform in ischemic
stroke in mice (33). In this study, we tried to adhere to the
STAIR criteria as much as possible, for example, by using mice
of different ages and both gender, transient and permanent
stroke models, and a long follow-up period, including eval-
uation by magnetic resonance imaging. The deletion of NOX4
dramatically protected mice from brain damage, resulting in a
75% reduction in infarct size, as did intrathecal application of
a pharmacological NOX inhibitor in wild-type mice (33).
Significantly, the drug was applied after the induction of is-
chemia, which from a clinical point is therapeutically much
more relevant than the prevention of brain damage before
the onset of ischemia as is the case in KO mice. Certainly,
the intrathecal route of administration is not optimal, and an
intravenous administration would be much more desirable
but was not possible due to pharmacokinetic limitations
of VAS2870, the inhibitor used in our study. Moreover,
this compound may have potential off-target effects (61),
which may make it less attractive for further development
into a drug.
However, that NOX4 is a promising target in stroke was
recently confirmed by another group using a transgenic
mouse model overexpressing NOX4 in endothelial cells (5).
Their findings are supportive of those seen in our global
NOX4 KO in that they found increased infarcts when com-
pared with wild-type mice. Mechanistically, this was hy-
pothesized to be due to suppression of endothelial NOS by
NOX4 (5). In accordance with these findings and the role of
endothelial NOX4, infarcts are smaller in endothelial cell-
specific NOX4 KO mice compared with wild-type littermates
(Radermacher, Kleinschnitz and Schmidt, unpublished ob-
servations).
It was recently suggested that NOX4-derived hydrogen
peroxide might also have a beneficial role in the cerebral cir-
culation by mediating cerebral vasodilatation and increasing
blood flow. However, this effect should be selective for the
ischemic zone, as a general cerebral vasodilation would rather
be harmful because of the ‘‘steal effect,’’ a phenomenon that
refers to the natural principle of the flow collateralization of
FIG. 4. Existing NOX4 knockout (KO) models. The NOX4
protein is composed of six transmembrane domains and
cytosolic binding domains for flavin adenine dinucleotide
(FAD) and nicotinamide adenine dinucleotide phosphate
(NADPH) at the C-terminus. Several groups have generated
NOX4 KO models by deleting different exons of the NOX4
gene. Our group’s NOX4 KO mouse was generated by de-
leting exons 14 and 15, which correspond to the NADPH
binding domain. This likely results in the expression of a
nonfunctional enzyme (33). Another NOX4 KO mouse was
generated by conditionally deleting exon 9 of NOX4 in car-
diomyocytes, thereby deleting the FAD binding domain (35).
The splice variants of NOX4 in different cell types and tissues
are not known. However, independent of which residual
protein would be expressed, these two KOs would be bio-
chemically inactive. In a third NOX4 KO model, exons 1 and
2 were deleted in an attempt to delete the NOX4 protein
completely (72). Another NOX4 KO model deleted exon 4
(9). Depending on alternative splicing, these may bear the
risk of truncated splice variants being expressed, which
contain the NADPH/FAD reductase domain. This domain is
able to generate ROS independently of the double heme
domain and may, thus, in some cells not eliminate NOX4-
dependent ROS formation, target it to different subcellular
compartments with different or no regulation. However, this
is a hypothetical risk, as the splicing in wild-type and KO
mice is not fully mapped. Alternatively, truncated NOX4
proteins, that is, without NADPH and/or FAD binding sites,
may affect other NOX isoforms in a dominant negative
fashion, for example, by scavenging p22phox. However, there
is no evidence as yet for this possibility (7).




















































arterial occlusions. To weigh the degree of potential harm
versus the benefit of inhibiting NOX4 and to approve or reject
this hypothesis, the effects of different NOX isoform-specific
inhibitors at different time points after stroke and also in
different species will be of interest. At present, all available
data clearly point toward an essential pathophysiological role
of NOX4 in ischemia-induced brain damage.
An accessory role for NOX2?
NOX2, a key enzyme of the innate immune and inflam-
matory response (48), is thought to be involved in almost
every cardiovascular disease setting (58), including I/R injury
(39). NOX2 was the first NOX homologue that was discov-
ered. Several studies have been performed to study the role of
NOX2 in stroke (8, 12, 13, 29, 32–34, 63, 66). These studies used
the same commercially available NOX2 KO mouse strain
(strain No. 002365 from Jackson), which had already been
generated in 1995 (47). Two of the studies (34, 66) reported
the use of wild-type littermates, while the remaining groups
used the recommended control animals from Jackson (strain
No. 000664).
The purpose of the first published NOX2 stroke study was
to elucidate the role of NADPH oxidases in neutrophil-
derived ROS in stroke injury. The authors investigated
whether deleterious NOX2 originates from influx of periph-
eral leucocytes and/or from activation of on-site microglia.
Although brain lesions were reduced by 46% in NOX2 KO
mice when compared with wild-type littermates, the amount
of neutrophils migrating into the brain was the same in NOX2
KO and wild-type mice. This raised the question whether
NOX2 implicated in brain damage originates from brain tis-
sue (neuronal or vascular origin) or from inflammatory cells.
Therefore, the authors transplanted bone marrow from wild-
type into NOX2 KO mice and vice versa, thus eliminating the
influence from circulating neutrophil-derived NOX2. Either
way, they observed no difference in infarct size, concluding
that the detrimental role of NOX2 involves the presence of
peripheral neutrophils in the infarcted brain (66). Fourteen
years later, Tang et al. repeated these experiments (63). Unlike
the procedure used in the first study of Walder et al. (66), Tang
et al. assessed different time points after bone marrow trans-
plantation and shielded the animal’s head to avoid a con-
founding induction of neuronal damage and microglia
activation by irradiation. They concluded that NOX2 from
peripheral immune cells contributes more to neurodegen-
eration than does microglia-derived NOX2 (63).
In NOX2 KO mice, the peak levels of ROS formation (72 h
poststroke) were attenuated and so were infarct volumes (34).
However, ROS were still detectable at that time, and other
sources of ROS (such as other NOX homologues) may still
play a role. With regard to infarct size observed in NOX2 KO
animals, the published data are conflicting. Most studies
suggest a protective effect of NOX2 deletion on stroke out-
comes. Initially, we could not reproduce these findings, al-
though we used a high number of animals and followed the
STAIR guidelines (33). More recently, we performed further
stroke experiments in an older cohort of NOX2 KO mice (20
weeks) in two different labs, amounting to a total of n = 21
wild-type and n = 14 KO mice. Pooling data from both centers,
we observed a small reduction in infarct size (Radermacher
et al., submitted for publication). Thus, the NOX2 isoform
seems to play a role in stroke pathology in elderly mice,
probably via its role in inflammatory processes. However, the
role of NOX2 appears to be more modest when compared
with that of NOX4. This and a possible publication bias
against studies with no or smaller effect sizes (45) may explain
some of the conflicting literature. Based on these divergent
results, a meta-analysis including all stroke studies performed
in NOX2 KO mice would be of interest. It may be that there are
other studies that did not find any protection by deleting
NOX2, which have not been published. Significantly, such a
potential publication bias should be revealed by a funnel plot.
This graphical method plots the result of each study (positive
or negative) against the sample size of the same study,
which—in the ideal case—results in an inverted funnel shape
peaking at the real effect size. An asymmetry of this funnel
indicates that studies are missing, either because they were
not found by the search strategy of the systematic review or as
they have not been published. This is important, because a
meta-analysis will only pool published data, thereby making
a null effect seem real. This analysis should not only be ap-
plied for the case of NOX2 KO mice, but would also be in-
teresting for NOX1 and NOX4 KO mice, once more stroke
studies have been published.
One important confounder that may explain the qualita-
tively different results could be inflammation. In human
stroke, the inflammatory response is thought to be at least
partly initiated to remove dead tissue. Factors that could po-
tentially influence the extent of inflammation and contribution
of NOX2 are the degree of aseptic surgery or a housing effect
(NOX2 KO mice are immune compromised and develop
granulomas). The more prominent the inflammation is, the
more prominent the role of NOX2 may become. Possibly, the
inflammation may also have the opposite effect by distracting
neutrophils that are removed from dead tissue to fight bacte-
ria. Interestingly, a paradoxical anti-inflammatory effect of
NOX2 was observed in autoimmune diseases (27), which
further complicates the considerations just mentioned.
After the publication of updated STAIR criteria, some re-
search groups started re-investigating the role of NOX2 under
influence of gender or comorbidities. Brait et al. (8) showed
that NOX2-dependent ROS production from T-lymphocytes
after stroke is increased during reperfusion, and that NOX2
only affects lesion size in male but not in female mice, possibly
because of estrogen having anti-inflammatory effects. Since
hypercholesterolemia is a frequent comorbidity in stroke pa-
tients, another group tested the neuroprotective drug betu-
linic acid in hypercholesterolemia-developing ApoE KO mice,
which had larger infarcts than wild-type mice. Betulinic acid
seemed to protect against stroke, probably via NOX2, neu-
ronal NOS, and inflammatory NOS down-regulation (40).
In conclusion, it is likely that both isoforms, NOX2 and
NOX4, are, to some extent, implicated in cerebral I/R injury,
depending on as yet unclear parameters. However, due to
higher neuroprotection that we have observed in NOX4 KO
mice and due to potential immunosuppressive effects of
NOX2 inhibition, we believe that NOX4 is the more promising
target for stroke therapy.
Pharmacological Approaches to Inhibit NOX Activity
In addition to using genetic animal models, another and
clinically more relevant option for validating NOX enzymes




















































as therapeutic targets is the use of pharmacological com-
pounds that selectively suppress NADPH oxidase activity.
The most widely used substances that inhibit NOX have been
apocynin and diphenylene iodonium (DPI) (Fig. 5). DPI al-
ready showed neuroprotection in vivo when administered
poststroke (43). However, its usefulness, initially demon-
strated as an inhibitor of phagocyte-related NOX, is limited,
as it also interacts with NOS and other flavoproteins (69).
Apocynin, a polyphenolic molecule with anti-inflammatory
properties, is thought to block the assembly of p47phox and
NOX2 and has to be activated by myeloperoxidases, which
are not present in all cells. The interpretation of studies using
apocynin is further complicated by its antioxidant capacity
(25) and inhibition of Rho kinase (52). Thus, classical NOX
inhibitors are not specific for NADPH oxidases, and, there-
fore, any results on the role of NADPH oxidase obtained by
using apocynin or DPI should be questioned (43, 57, 69, 71). A
more specific NOX inhibitor is the triazolopyrimidine
VAS2870 (Fig. 5), which already proved its protective effects
in preclinical stroke experiments (33). VAS2870 and its deri-
vate VAS3947 likely inhibit all NOX isoforms and are neither
general flavoprotein inhibitors nor ROS scavengers (64, 69).
Mechanistically, VAS2870 seems to be a pan-NOX inhibitor
(70), as it inhibits assembly or conformational changes to ac-
tive NOX complexes (3). When a complex assembly of NOX2
with its cytosolic binding proteins was induced before the
addition of VAS2870, no inhibition of NOX activity was ob-
served (3, 21). When VAS2870 was added before complex
assembly induction, inhibition of NOX2 activity was ob-
served (3). Therefore, the order by which a NOX complex
assembly activator and a NOX inhibitor are added in cell-free
assays is crucial. Very recently, potential off-target effects of
VAS2870 have been published, suggesting that the compound
alkylates cysteine thiol residues (61). The authors suggest that
thio-alkylation of cysteine residues may play a role in NOX
inhibition. Nevertheless, the importance of this off-target al-
kylation in the presence of physiological glutathione concen-
trations and the occurrence of other off-target effects of
VAS2870 need to be further analyzed in a more extended off-
target screen.
Beside VAS compounds, which are general NOX inhibitors,
NOX isoform-specific inhibitors may represent a better tool
for assessing the role of individual NOX isoforms and also for
developing experimental therapeutics. One approach was to
use peptides, such as the chimeric peptide, gp91ds-tat (50),
which combines the p47phox docking sequence of NOX2 with
the cell penetrating tat peptide (Fig. 6). This peptide not only
prevents NOX assembly and is relatively specific for NOX2,
but also potentially inhibits NOX1 (50). However, off-target
effects of gp91ds-tat have been described in vivo (2). More
recently, a selective NOX1/4 inhibitor, the pyrazolopyridine
derivate GKT136901, was introduced (Fig. 6) (36).
To validate NADPH oxidases as a target for stroke therapy,
apocynin has mostly been used as NOX inhibitor. Jackman
et al. (29) showed that apocynin given prestroke caused a re-
duction in infarct size, but not when administered poststroke.
Indeed, in most studies, apocynin was given before stroke
onset (32, 62, 67), a procedure that does not allow statements
on therapeutic relevance in a clinical setting, where any
therapy has to work poststroke. Tang et al. did not find any
additional neuroprotection in apocynin-treated mice on top of
NOX2 gene deletion (63). Does this exclude a role for another
NOX isoform in ischemia-induced brain damage? This is
probably not the case, as apocynin interferes with p47phox
binding to NOX and NOX activation. However, NOX4 does
not seem to depend on p47phox (41). Neuroprotective effects
of the NOX inhibitor VAS2870 have been demonstrated
when injected intrathecally into the spinal liquor space of
wild-type mice, but did not mediate any further protection
in NOX4 KO mice, suggesting that NOX4 is the major det-
rimental player (33). Nevertheless, stroke experiments with
other, more isoform-specific NOX inhibitors would be of
great interest. Alternatively, NOX activity can also be re-
pressed by using small interfering RNAs (3), but the
FIG. 5. NOX inhibitors assessed for their neuroprotective
potential. The figure displays chemical structures of NOX-
inhibiting compounds that have been tested as therapeutics
in cerebral infarction. All of them have been shown to suc-
cessfully reduce infarct size after ischemic stroke. Since
apocynin and diphenylene iodonium (DPI) are not suffi-
ciently specific for NADPH oxidases, their application in vivo
is limited due to many off-target effects. VAS2870 seems to
be more specific for NOX, although off-target effects cannot
be excluded and due to poor solubility, the intrathecal mode
of administration is used, which is not optimal.
FIG. 6. Promising NOX inhibitors to be tested in pre-
clinical stroke research. The VAS2870 derivate VAS3947
does not differ from VAS2870 in its NOX inhibition profile,
but it may be better suited for in vivo application because of
its better solubility. The peptidic inhibitor gp91ds-tat inter-
feres with the assembly between NOX2 and p47phox, which
renders it NOX2 selective. An inhibition of NOX1 could also
be imaginable, as the NOX1 activity also depends on subunit
regulation by p47phox. Another promising NOX inhibitor,
GKT136901, has been reported to mainly inhibit NOX1 and
NOX4.




















































interference of siRNA with other than the intended NOX
isoform has to be excluded (53).
Conclusion
In conclusion, NOX4 and, possibly to a lesser extent, NOX2
appear to play a role in ischemic stroke. Both are up-regulated
in human stroke, and experiments with experimental com-
pounds suggest that NOX inhibition may be relevant for a
highly innovative neuroprotective poststroke therapy.
Clearly, further studies using different KO models and in-
hibitors in different species are needed to fully validate the
NOX isoform that is the most promising target and a possible
time window for further development.
Acknowledgments
The authors wish to acknowledge national and interna-
tional competitive grant support by the NHMRC, EU and
ERC (HHHW), the Brain Foundation of the Netherlands (KR),
and DFG (CK). Work performed at the German Mouse Clinic
was funded by grants from the German Federal Ministry of
Education and Research (BMBF, NGFN-Plus grants No.
01GS0850, 01GS0851, and 01GS0854).
Author Disclosure Statement
H.H.H.W.S. is a cofounder of Vasopharm GmbH,
which is developing NOX inhibitors. C.K. has received
funding from Novartis Pharma GmbH, Nürnberg, Germany,
to conduct research on NADPH oxidase.
References
1. Ago T, Kitazono T, Kuroda J, Kumai Y, Kamouchi M, Oo-
boshi H, Wakisaka M, Kawahara T, Rokutan K, Ibayashi S,
and Iida M. NAD(P)H oxidases in rat basilar arterial endo-
thelial cells. Stroke 36: 1040–1046, 2005.
2. Aldieri E, Riganti C, Polimeni M, Gazzano E, Lussiana C,
Campia I, and Ghigo D. Classical inhibitors of NOX
NAD(P)H oxidases are not specific. Curr Drug Metab 9: 686–
696, 2008.
3. Altenhofer S, Kleikers PW, Radermacher KA, Scheurer P,
Rob Hermans JJ, Schiffers P, Ho H, Wingler K, and Schmidt
HH. The NOX toolbox: validating the role of NADPH oxi-
dases in physiology and disease. Cell Mol Life Sci 69: 2327–
2343, 2012.
4. Anilkumar N, Weber R, Zhang M, Brewer A, and Shah AM.
Nox4 and nox2 NADPH oxidases mediate distinct cellular
redox signaling responses to agonist stimulation. Arterioscler
Thromb Vasc Biol 28: 1347–1354, 2008.
5. Arimura K, Ago T, Kuroda J, Ishitsuka K, Nishimura A,
Sugimori H, Kamouchi M, Sasaki T, and Kitazono T. Role of
NADPH oxidase 4 in Brain Endothelial cells after Ischemic
Stroke. Stroke 43: A2514, 2012.
6. Bedard K and Krause KH. The NOX family of ROS-
generating NADPH oxidases: physiology and pathophysio-
logy. Physiol Rev 87: 245–313, 2007.
7. Ben Mkaddem S, Pedruzzi E, Werts C, Coant N, Bens M,
Cluzeaud F, Goujon JM, Ogier-Denis E, and Vandewalle A.
Heat shock protein gp96 and NAD(P)H oxidase 4 play
key roles in Toll-like receptor 4-activated apoptosis during
renal ischemia/reperfusion injury. Cell Death Differ 17: 1474–
1485, 2010.
8. Brait VH, Jackman KA, Walduck AK, Selemidis S, Diep H,
Mast AE, Guida E, Broughton BR, Drummond GR, and
Sobey CG. Mechanisms contributing to cerebral infarct
size after stroke: gender, reperfusion, T lymphocytes, and
Nox2-derived superoxide. J Cereb Blood Flow Metab 30: 1306–
1317, 2010.
9. Carnesecchi S, Deffert C, Donati Y, Basset O, Hinz B, Prey-
nat-Seauve O, Guichard C, Arbiser JL, Banfi B, Pache JC,
Barazzone-Argiroffo C, and Krause KH. A key role for
NOX4 in epithelial cell death during development of lung
fibrosis. Antioxid Redox Signal 15: 607–619, 2011.
10. Chan PH. Role of oxidants in ischemic brain damage. Stroke
27: 1124–1129, 1996.
11. Chan PH. Reactive oxygen radicals in signaling and damage
in the ischemic brain. J Cereb Blood Flow Metab 21: 2–14, 2001.
12. Chen H, Kim GS, Okami N, Narasimhan P, and Chan PH.
NADPH oxidase is involved in post-ischemic brain inflam-
mation. Neurobiol Dis 42: 341–348, 2011.
13. Chen H, Song YS, and Chan PH. Inhibition of NADPH ox-
idase is neuroprotective after ischemia-reperfusion. J Cereb
Blood Flow Metab 29: 1262–1272, 2009.
14. Den Hertog HM, van der Worp HB, Tseng MC, and Dippel
DW. Cooling therapy for acute stroke. Cochrane Database Syst
Rev: CD001247, 2009.
15. Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis
SM, Shuaib A, Ashwood T, Wasiewski W, Alderfer V,
Hardemark HG, and Rodichok L. NXY-059 for the treatment
of acute stroke: pooled analysis of the SAINT I and II Trials.
Stroke 39: 1751–1758, 2008.
16. Dirnagl U and Fisher M. International, multicenter ran-
domized preclinical trials in translational stroke research: It’s
time to act. J Cereb Blood Flow Metab 32: 933–935, 2012.
17. Dirnagl U and Fisher M. REPRINT: international, multi-
center randomized preclinical trials in translational stroke
research: it is time to act. Stroke 43: 1453–1454, 2012.
18. Eisener-Dorman AF, Lawrence DA, and Bolivar VJ. Cau-
tionary insights on knockout mouse studies: the gene or not
the gene? Brain Behav Immun 23: 318–324, 2009.
19. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA,
Savitz SI, and Lo EH. Update of the stroke therapy academic
industry roundtable preclinical recommendations. Stroke 40:
2244–2250, 2009.
20. Flamm ES, Demopoulos HB, Seligman ML, Poser RG,
and Ransohoff J. Free radicals in cerebral ischemia. Stroke 9:
445–447, 1978.
21. Gatto GJ, Ao Z, Kearse MG, Zhou M, Morales CR, Daniels
E, Bradley BT, Goserud MT, Goodman KB, Douglas SA,
Harpel MR, and Johns DG. NADPH oxidase-dependent
and -independent mechanisms of reported inhibitors of
reactive oxygen generation. J Enzyme Inhibit Med Chem
2011 [Epub ahead of print]; DOI:10.3109/14756366.2011.
636360.
22. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT,
Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RG,
Hinchey JA, Howard VJ, Jauch EC, Levine SR, Meschia JF,
Moore WS, Nixon JV, and Pearson TA. Guidelines for the
primary prevention of stroke: a guideline for healthcare
professionals from the American Heart Association/Ameri-
can Stroke Association. Stroke 42: 517–584, 2011.
23. Green SP, Cairns B, Rae J, Errett-Baroncini C, Hongo JA,
Erickson RW, and Curnutte JT. Induction of gp91-phox, a
component of the phagocyte NADPH oxidase, in microglial
cells during central nervous system inflammation. J Cereb
Blood Flow Metab 21: 374–384, 2001.




















































24. Halliwell B. Phagocyte-derived reactive species: salvation or
suicide? Trends Biochem Sci 31: 509–515, 2006.
25. Heumuller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse
R, Schroder K, and Brandes RP. Apocynin is not an inhibitor
of vascular NADPH oxidases but an antioxidant. Hyperten-
sion 51: 211–217, 2008.
26. Howells DW, Porritt MJ, Rewell SS, O’Collins V, Sena ES,
van der Worp HB, Traystman RJ, and Macleod MR. Differ-
ent strokes for different folks: the rich diversity of animal
models of focal cerebral ischemia. J Cereb Blood Flow Metab
30: 1412–1431, 2010.
27. Hultqvist M, Olsson LM, Gelderman KA, and Holmdahl R.
The protective role of ROS in autoimmune disease. Trends
Immunol 30: 201–208, 2009.
28. Infanger DW, Sharma RV, and Davisson RL. NADPH oxi-
dases of the brain: distribution, regulation, and function.
Antioxid Redox Signal 8: 1583–1596, 2006.
29. Jackman KA, Miller AA, De Silva TM, Crack PJ, Drummond
GR, and Sobey CG. Reduction of cerebral infarct volume by
apocynin requires pretreatment and is absent in Nox2-defi-
cient mice. Br J Pharmacol 156: 680–688, 2009.
30. Jackman KA, Miller AA, Drummond GR, and Sobey CG.
Importance of NOX1 for angiotensin II-induced cerebro-
vascular superoxide production and cortical infarct volume
following ischemic stroke. Brain Res 1286: 215–220, 2009.
31. Kahles T, Kohnen A, Heumueller S, Rappert A, Bechmann I,
Liebner S, Wittko IM, Neumann-Haefelin T, Steinmetz H,
Schroeder K, and Brandes RP. NADPH oxidase Nox1 con-
tributes to ischemic injury in experimental stroke in mice.
Neurobiol Dis 40: 185–192, 2010.
32. Kahles T, Luedike P, Endres M, Galla HJ, Steinmetz H, Busse
R, Neumann-Haefelin T, and Brandes RP. NADPH oxidase
plays a central role in blood-brain barrier damage in ex-
perimental stroke. Stroke 38: 3000–3006, 2007.
33. Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones E,
Mittal M, Barit D, Schwarz T, Geis C, Kraft P, Barthel K,
Schuhmann MK, Herrmann AM, Meuth SG, Stoll G, Meurer
S, Schrewe A, Becker L, Gailus-Durner V, Fuchs H, Klop-
stock T, de Angelis MH, Jandeleit-Dahm K, Shah AM,
Weissmann N, and Schmidt HH. Post-stroke inhibition of
induced NADPH oxidase type 4 prevents oxidative stress
and neurodegeneration. PLoS Biol 8: e1000479, 2010.
34. Kunz A, Anrather J, Zhou P, Orio M, and Iadecola C. Cy-
clooxygenase-2 does not contribute to postischemic pro-
duction of reactive oxygen species. J Cereb Blood Flow Metab
27: 545–551, 2007.
35. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, and
Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of
oxidative stress in the failing heart. Proc Natl Acad Sci U S A
107: 15565–15570, 2010.
36. Laleu B, Gaggini F, Orchard M, Fioraso-Cartier L, Cagnon L,
Houngninou-Molango S, Gradia A, Duboux G, Merlot C,
Heitz F, Szyndralewiez C, and Page P. First in class, potent,
and orally bioavailable NADPH oxidase isoform 4 (Nox4)
inhibitors for the treatment of idiopathic pulmonary fibrosis.
J Med Chem 53: 7715–7730, 2010.
37. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Di-
ener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, and
Wasiewski WW. NXY-059 for acute ischemic stroke. N Engl J
Med 354: 588–600, 2006.
38. Levy DE, del Zoppo GJ, Demaerschalk BM, Demchuk AM,
Diener HC, Howard G, Kaste M, Pancioli AM, Ringelstein
EB, Spatareanu C, and Wasiewski WW. Ancrod in acute
ischemic stroke: results of 500 subjects beginning treatment
within 6 hours of stroke onset in the ancrod stroke program.
Stroke 40: 3796–3803, 2009.
39. Loukogeorgakis SP, van den Berg MJ, Sofat R, Nitsch D,
Charakida M, Haiyee B, de Groot E, MacAllister RJ, Kuijpers
TW, and Deanfield JE. Role of NADPH oxidase in endo-
thelial ischemia/reperfusion injury in humans. Circulation
121: 2310–2316, 2010.
40. Lu Q, Xia N, Xu H, Guo L, Wenzel P, Daiber A, Munzel T,
Forstermann U, and Li H. Betulinic acid protects against
cerebral ischemia-reperfusion injury in mice by reducing
oxidative and nitrosative stress. Nitric Oxide Biol Chem 24:
132–138, 2011.
41. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC,
and Knaus UG. Functional analysis of Nox4 reveals unique
characteristics compared to other NADPH oxidases. Cell
Signal 18: 69–82, 2006.
42. Miller AA, Drummond GR, Schmidt HH, and Sobey
CG. NADPH oxidase activity and function are profoundly
greater in cerebral versus systemic arteries. Circ Res 97:
1055–1062, 2005.
43. Nagel S, Genius J, Heiland S, Horstmann S, Gardner H, and
Wagner S. Diphenyleneiodonium and dimethylsulfoxide for
treatment of reperfusion injury in cerebral ischemia of the
rat. Brain Res 1132: 210–217, 2007.
44. O’Collins VE, Donnan GA, and Howells DW. History of
animal models of stroke. Stroke 6: 77–78, 2011.
45. O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der
Worp BH, and Howells DW. 1,026 experimental treatments
in acute stroke. Ann Neurol 59: 467–477, 2006.
46. Opitz N, Drummond GR, Selemidis S, Meurer S, and
Schmidt HH. The ‘A’s and ‘O’s of NADPH oxidase regula-
tion: a commentary on ‘‘Subcellular localization and func-
tion of alternatively spliced Noxo1 isoforms’’. Free Radic Biol
Med 42: 175–179, 2007.
47. Pollock JD, Williams DA, Gifford MA, Li LL, Du X, Fisher-
man J, Orkin SH, Doerschuk CM, and Dinauer MC. Mouse
model of X-linked chronic granulomatous disease, an in-
herited defect in phagocyte superoxide production. Nat
Genet 9: 202–209, 1995.
48. Rada B and Leto TL. Oxidative innate immune defenses by
Nox/Duox family NADPH oxidases. Contrib Microbiol 15:
164–187, 2008.
49. Radermacher KA, Wingler K, Kleikers PW, Altenhofer SA,
Hermans JR, Kleinschnitz C, and Schmidt HH. The 1027th
target candidate in stroke: Will NADPH oxidase hold up?
Exp Transl Stroke Med 4: 11, 2012.
50. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, and Pagano PJ.
Novel competitive inhibitor of NAD(P)H oxidase assembly
attenuates vascular O(2)(-) and systolic blood pressure in
mice. Circ Res 89: 408–414, 2001.
51. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD,
Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton
HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela
BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD,
Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS,
Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soli-
man EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS,
Wong ND, Woo D, and Turner MB. Heart disease and stroke
statistics—2012 update: a report from the american heart
association. Circulation 125: e2–e220, 2012.
52. Schluter T, Steinbach AC, Steffen A, Rettig R, and Grisk O.
Apocynin-induced vasodilation involves Rho kinase inhibi-
tion but not NADPH oxidase inhibition. Cardiovasc Res 80:
271–279, 2008.




















































53. Schroder K, Wandzioch K, Helmcke I, and Brandes RP.
Nox4 acts as a switch between differentiation and prolifer-
ation in preadipocytes. Arterioscler Thromb Vasc Biol 29: 239–
245, 2009.
54. Sena E, van der Worp HB, Howells D, and Macleod M. How
can we improve the pre-clinical development of drugs for
stroke? Trends Neurosci 30: 433–439, 2007.
55. Sena ES, van der Worp HB, Bath PM, Howells DW, and
Macleod MR. Publication bias in reports of animal stroke
studies leads to major overstatement of efficacy. PLoS Biol 8:
e1000344, 2010.
56. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM,
Diener HC, Ashwood T, Wasiewski WW, and Emeribe U.
NXY-059 for the treatment of acute ischemic stroke. N Engl J
Med 357: 562–571, 2007.
57. Simonyi A, Serfozo P, Lehmidi TM, Cui J, Gu Z, Lubahn DB,
Sun AY, and Sun GY. The neuroprotective effects of apoc-
ynin. Front Biosci 4: 2183–2193, 2012.
58. Sirker A, Zhang M, and Shah AM. NADPH oxidases in
cardiovascular disease: insights from in vivo models and
clinical studies. Basic Res Cardiol 106: 735–747, 2011.
59. Sorce S and Krause KH. NOX enzymes in the central ner-
vous system: from signaling to disease. Antioxid Redox Signal
11: 2481–2504, 2009.
60. STAIR. Recommendations for standards regarding preclini-
cal neuroprotective and restorative drug development.
Stroke 30: 2752–2758, 1999.
61. Sun QA, Hess DT, Wang B, Miyagi M, and Stamler JS. Off-
target thiol alkylation by the NADPH oxidase inhibitor 3-
benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo[4,5-d]pyrimidine
(VAS2870). Free Radic Biol Med 52: 1897–1902, 2012.
62. Tang XN, Cairns B, Cairns N, and Yenari MA. Apocynin
improves outcome in experimental stroke with a narrow
dose range. Neuroscience 154: 556–562, 2008.
63. Tang XN, Zheng Z, Giffard RG, and Yenari MA. Significance
of marrow-derived nicotinamide adenine dinucleotide
phosphate oxidase in experimental ischemic stroke. Ann
Neurol 70: 606–615, 2011.
64. ten Freyhaus H, Huntgeburth M, Wingler K, Schnitker J,
Baumer AT, Vantler M, Bekhite MM, Wartenberg M, Sauer
H, and Rosenkranz S. Novel Nox inhibitor VAS2870 atten-
uates PDGF-dependent smooth muscle cell chemotaxis, but
not proliferation. Cardiovasc Res 71: 331–341, 2006.
65. Vallet P, Charnay Y, Steger K, Ogier-Denis E, Kovari E,
Herrmann F, Michel JP, and Szanto I. Neuronal expression of
the NADPH oxidase NOX4, and its regulation in mouse ex-
perimental brain ischemia. Neuroscience 132: 233–238, 2005.
66. Walder CE, Green SP, Darbonne WC, Mathias J, Rae J, Di-
nauer MC, Curnutte JT, and Thomas GR. Ischemic stroke
injury is reduced in mice lacking a functional NADPH oxi-
dase. Stroke 28: 2252–2258, 1997.
67. Wang Q, Tompkins KD, Simonyi A, Korthuis RJ, Sun AY,
and Sun GY. Apocynin protects against global cerebral is-
chemia-reperfusion-induced oxidative stress and injury in
the gerbil hippocampus. Brain Res 1090: 182–189, 2006.
68. Warner DS, Sheng H, and Batinic-Haberle I. Oxidants,
antioxidants and the ischemic brain. J Exp Biol 207: 3221–
3231, 2004.
69. Wind S, Beuerlein K, Eucker T, Muller H, Scheurer P, Ar-
mitage ME, Ho H, Schmidt HH, and Wingler K. Compara-
tive pharmacology of chemically distinct NADPH oxidase
inhibitors. Br J Pharmacol 161: 885–898, 2010.
70. Wingler K, Altenhoefer SA, Kleikers PW, Radermacher KA,
Kleinschnitz C, and Schmidt HH. VAS2870 is a pan-NADPH
oxidase inhibitor. Cell Mol Life Sci 69: 3159–3160, 2012.
71. Wingler K, Hermans J, Schiffers P, Moens A, Paul M, and
Schmidt H. NOX 1, 2, 4, 5: Counting out oxidative stress. Br J
Pharmacol 164: 866–883, 2011.
72. Zhang M, Brewer AC, Schroder K, Santos CX, Grieve DJ,
Wang M, Anilkumar N, Yu B, Dong X, Walker SJ, Brandes
RP, and Shah AM. NADPH oxidase-4 mediates protection
against chronic load-induced stress in mouse hearts by en-
hancing angiogenesis. Proc Natl Acad Sci U S A 107: 18121–
18126, 2010.
Address correspondence to:







Date of first submission to ARS Central, July 6, 2012; date of













NOX¼ catalytic subunit of NADPH oxidases
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